Aandelen in “Fabricage van farmaceutische preparaten”

Aandeel Datum Koers Evolutie
vlag Eagle Pharmaceuticals Inc 25/09 1,025 USD
+13,89% 		+13,89%
vlag Edesa Biotech Inc 25/09 4,010 USD
-0,50% 		-0,50%
vlag Elanco Animal Health Inc 25/09 22,310 USD
-0,18% 		-0,18%
vlag Eli Lilly 25/09 1.183,460 USD
+0,13% 		+0,13%
vlag Emergent Biosolutions Inc 25/09 6,790 USD
+0,30% 		+0,30%
vlag Enanta Pharmaceuticals Inc 25/09 11,880 USD
-1,00% 		-1,00%
vlag Enlivex Therapeutics Ltd 25/09 0,598 USD
-1,27% 		-1,27%
vlag Equillium Inc 25/09 1,670 USD
-2,91% 		-2,91%
vlag Esports Entertainment Group Inc 25/09 0,145 USD
+20,83% 		+20,83%
vlag Evofem Biosciences Inc 25/09 0,008 USD
0,00% 		0,00%
vlag Evotec SE 25/09 2,810 EUR
+2,03% 		+2,03%

Nieuws over “Fabricage van farmaceutische preparaten”

26/09 · Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? · Persbericht

26/09 · Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? · Persbericht

26/09 · Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation - GERN · Persbericht

25/09 · FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata · Persbericht

25/09 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

25/09 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

25/09 · Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study · Persbericht

25/09 · Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma · Persbericht

25/09 · Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior · Persbericht

24/09 · CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline · Persbericht

24/09 · SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX · Persbericht

24/09 · SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - CAPR · Persbericht

24/09 · Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes · Persbericht

24/09 · U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes · Persbericht

24/09 · Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026 · Persbericht

23/09 · Teva Releases Q3 2026 Aide Memoire · Persbericht

23/09 · Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET · Persbericht

23/09 · Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes · Persbericht

23/09 · Zymeworks Completes Acquisition of Theravance Biopharma · Persbericht

23/09 · 'De beursvoyeurs' met jonge belegger Dora Wallays: ‘Niet beleggen is óók een risico’ · Tijd.be (€)

Ze kreeg van haar vader 2.000 euro om haar eerste stappen op de beurs te zetten en is sindsdien niet meer gestopt. In 'De beursvoyeurs' vertelt de jonge belegger Dora Wallays waarom een flink deel van haar loon automatisch...

23/09 · Levi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 16, 2026 - ARDX · Persbericht

Mijn selecties